Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

Jonathan Hoggatt,1 Tiffany A Tate,1 Louis M Pelus2 1Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; 2Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Chemotherapy, irradiation, and other age...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hoggatt J, Tate TA, Pelus LM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d1e3f98579804b9c81d3d3eb9b386d6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d1e3f98579804b9c81d3d3eb9b386d6e
record_format	dspace
spelling	oai:doaj.org-article:d1e3f98579804b9c81d3d3eb9b386d6e2021-12-02T04:55:03ZRole of lipegfilgrastim in the management of chemotherapy-induced neutropenia1178-2013https://doaj.org/article/d1e3f98579804b9c81d3d3eb9b386d6e2015-04-01T00:00:00Zhttp://www.dovepress.com/role-of-lipegfilgrastim-in-the-management-of-chemotherapy-induced-neut-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Jonathan Hoggatt,1 Tiffany A Tate,1 Louis M Pelus2 1Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; 2Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen®) and pegfilgrastim (Neulasta®). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex®), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace. Keywords: granulocyte-colony stimulating factor, biosimilar, filgrastim, neutrophil, XM22, cancerHoggatt JTate TAPelus LMDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 2647-2652 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hoggatt J Tate TA Pelus LM Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
description	Jonathan Hoggatt,1 Tiffany A Tate,1 Louis M Pelus2 1Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; 2Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen®) and pegfilgrastim (Neulasta®). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex®), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace. Keywords: granulocyte-colony stimulating factor, biosimilar, filgrastim, neutrophil, XM22, cancer
format	article
author	Hoggatt J Tate TA Pelus LM
author_facet	Hoggatt J Tate TA Pelus LM
author_sort	Hoggatt J
title	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
title_short	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
title_full	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
title_fullStr	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
title_full_unstemmed	Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
title_sort	role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/d1e3f98579804b9c81d3d3eb9b386d6e
work_keys_str_mv	AT hoggattj roleoflipegfilgrastiminthemanagementofchemotherapyinducedneutropenia AT tateta roleoflipegfilgrastiminthemanagementofchemotherapyinducedneutropenia AT peluslm roleoflipegfilgrastiminthemanagementofchemotherapyinducedneutropenia
_version_	1718401035627659264

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

Ejemplares similares